Drug Trial Radar · NCT01953588
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,473
Actual
Start
Feb 27, 2014
Primary completion
Apr 1, 2027
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug Administration (FDA) of the United States for use after surgery for postmenopausal women with estrogen receptor positive breast cancer. It is also considered a standard of care to give anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved by the FDA for use in women with early stage breast cancer before or after surgery, but is approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast cancer that has spread to other parts of the body.
Conditions
- Estrogen Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- Invasive Ductal Breast Carcinoma
- Invasive Lobular Breast Carcinoma
- Recurrent Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
Interventions
fulvestrantDrug
Fulvestrant 500 mg IM
anastrozoleDrug
Anastrozole 1 mg oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of endocrine resistant disease-(First Phase)Time frame: Up to 24 weeks
- Recurrence-free survival (RFS)-(Second Phase)Time frame: Up to 5 years
Locations
860 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Regional Hospital
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
University of Arizona Cancer Center at Saint Joseph's
Phoenix, Arizona
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
Yuma Cancer Center
Yuma, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
Highlands Oncology Group-Rogers
Rogers, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
Community Cancer Institute
Clovis, California
University Oncology Associates
Clovis, California
Sutter Davis Hospital
Davis, California
Epic Care-Dublin
Dublin, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Showing 40 of 860 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.